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Breastfeeding: a reproductive factor able to reduce the risk of
luminal B breast cancer in premenopausal White women
Fabiola Giudicia,*, Bruna Scaggianteb,*, Serena Scomersic, Marina Bortula,c,
Maura Tonuttic and Fabrizio Zanconatia,c
In the medical literature, the role of breastfeeding and
reproductive factors in the risk of breast carcinoma is still an
open debate in premenopausal women. We highlight the role
of breastfeeding and reproductive factors in luminal A and
luminal B, the most frequent breast cancers. This
case–control study analyzes a White premenopausal
population of 286 breast cancer patients, divided into
molecular subtypes, and 578 controls matched by age.
Multivariate logistic regression models were used to assess
the relationships of breastfeeding and other reproductive
factors (age at menarche, parity, age at first pregnancy,
number of children) with the risk of breast cancers. Among
the variables examined, reproductive factors did not alter the
risk of cancer, whereas breastfeeding up to 12 months was a
significant protective factor against luminal B breast cancer
(multivariate odds ratio: 0.22, 95% confidence interval:
0.09–0.59, P=0.002). In contrast, luminal A cases did not
significantly correlate with breastfeeding or other
reproductive factors. Breastfeeding up to 12 months is
strongly protective against the more aggressive luminal B,
but not against the less aggressive luminal A breast cancer in
premenopausal White women. European Journal of Cancer
Prevention 26:217–224 Copyright © 2017 The Author(s).
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Introduction
Breast cancer is the leading cause of cancer death among
women worldwide (Siegel et al., 2015). Several studies
and meta-analyses have shown that reproductive factors
are associated with the risk of breast cancer (Kelsey et al.,
1993; Yang and Jacobsen, 2008; Butt et al., 2014). The
underlying biological mechanisms are not yet clearly
understood, but epidemiological evidence indicates that
early menarche, older age at first full-term pregnancy, low
parity, and lack of breastfeeding increase the risk of
breast cancer (Kelsey et al., 1993; Collaborative Group on
Hormonal Factors in Breast Cancer, 2002).
A protective effect of breastfeeding has been indicated
(Collaborative Group on Hormonal Factors in Breast
Cancer, 2002; Ursin et al., 2005; Ma et al., 2006; Horn
et al., 2014), but the majority of published findings often
present results for a mix of both premenopausal and
postmenopausal women (Ursin et al., 2005; Butt et al.,
2014) or only for postmenopausal women (Phipps et al.,
2008; Horn et al., 2014). Recently, several studies have
assessed the role of breastfeeding and other reproductive
factors in different breast cancer subtypes, suggesting
that the association of reproductive factors with the risk
of breast cancer may vary according to breast cancer
molecular profiles (Ursin et al., 2005; Phipps et al., 2008;
Horn et al., 2014). The identification of which factors are
related to the risk of breast cancer in populations of
women identified by menopausal status, age, race, and
molecular cancer subtypes still deserves further investi-
gation (Warner et al., 2013; Horn et al., 2014). In parti-
cular, it remains to be clarified whether breastfeeding
could exert a protective effect on breast cancers in pre-
menopausal women (Negri et al., 1996; Ferlay et al., 2013;
Butt et al., 2014).
This study investigates in a case–control population of
White premenopausal women living in a country with a
high breast cancer incidence the role of breastfeeding
and reproductive factors on the risk of breast cancer
stratified into molecular cancer subtypes. In particular,
we analyzed the luminal breast cancers, accounting for
about 75% of all breast cancers (Azim and Partridge,
2014; Rotunno et al., 2014).
Patients and methods
Study cohort
We selected a homogeneous population of White pre-
menopausal women living for at least 10 years in Trieste
(Friuli-Venezia Giulia), an Italian region with the highest
incidence of breast cancer: estimated age-standardized
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rates (ASRs) for Europe 94.2, ASRs for Italy 118.0, and
ASRs for Friuli-Venezia Giulia 129.1 (European stan-
dard) (Ferlay et al., 2013; Zucchetto et al., 2013).
Premenopausal women were enrolled by Azienda
Ospedaliera ‘Ospedali Riuniti’ of Trieste (Italy) between
January 2006 and January 2014. The case patients had
received a histopathologically confirmed first diagnosis of
primary breast cancer between 2006 and 2013. The
control participants were women who spontaneously
joined breast cancer-prevention campaigns between 2009
and 2014; they had no breast diseases, which was con-
firmed by medical records. The cohort of women
between 21 and 49 years of age were premenopausal
(regular menstrual flow in the last year at the interview).
Cases were age adjusted and matched with two controls
with an age interval of 5 years. The Mann–Whitney test
confirmed the pairing.
Data collection questionnaire
Women were invited to fill out a questionnaire on demo-
graphics, reproductive history, breast pathology, BMI, and
lifestyle. Reproductive history included questions on age
an menarche, parity (defined by the number of full-term
pregnancies), age at first full-term pregnancy, overall
duration of breastfeeding (≤ 12 months, > 12 months), and
menopausal status.
Questions on familial breast cancer history were included
according to NICE guidelines (National Institute for
Health and Care Excellence Pathway, created: October
2011, last updated: December 2013). Consent to the
processing of data in an anonymous form for clinical
research, epidemiology, and training (and with the aim
of improving knowledge, treatment and prevention), in
agreement with the Italian law art.81 D.lgs 196/2003, sez.
D, was obtained at the diagnosis of cases by the hospital.
For each case and control, we obtained a signed infor-
mant consent during the interview to use the data in an
anonymous form, in agreement with the Italian law art.81
D.lgs 196/2003, sez. D.
Physicians always conducted the structured ques-
tionnaire and the interviews lasted about 20 min.
Data collection on breast cancer and molecular profiles
Histopathological features and data on estrogen receptor
(ER), progesterone receptor (PR), and HER2 expression
status were obtained from records. All invasive tumors
were re-evaluated by pathologists to confirm aggressive-
ness and tumor type according to the WHO classification.
Classification of molecular subtypes takes into account
the expression of ER, PR, HER2, and Ki-67 according to
St. Gallen 2013 (Goldhirsch et al., 2013).
All tests of ER, PR, and HER2 expression were based on
immunohistochemistry testing. In equivocal HER2 cases,
data from fluorescent in-situ hybridization assay records
were used for molecular stratification. Patients with
incomplete data on tumor markers were excluded from
the study population. Breast cancer subtypes were
grouped into the following categories: in-situ carcinomas,
luminal A cases (ER+ /PR+ /HER2− , Ki-67< 20%),
luminal B cases (luminal B HER2− : HER+ /HER2−
and at least one of Ki-67≥ 20% or PR− , luminal B
HER2+ : ER+ /HER2+ /any Ki-67/any PR), HER2+
(ER− /PR− /HER2+ ), and triple-negative breast cancers
(ER− /PR− /HER2− ).
The Ki-67 protein was evaluated on formalin-fixed tissue
samples by the Joint Commission Accredited Hospital
Laboratory using an automatic stainer (Lab Vision;
Thermo Scientific, Runcorn, UK). The reaction with
monoclonal antibody clone MIB-1 (Bio-Optica MILANO
S.p.A, Milan, Italy; 1 : 200 dilution) was followed by
HRP–DAB staining [UltraVision LP (Thermo Scientific);
and DAB Quanto (Thermo Scientific)].
The HER2 monoclonal antibody was clone CB-11
(1 : 300 dilution; Aczon Biotech S.p.A, Bologna, Italy);
the reactivity was evaluated using the detection kit
HRP–DAB (Thermo Scientific). Every slide was eval-
uated by a pathologist on an optical microscope with a
low magnification (×10) and classified as positive, nega-
tive, or equivocal, in agreement with the guidelines of
the American Society of Clinical Oncology and College of
American Pathologists (ASCO-CAP, 2006; Wolff et al.,
2007).
Statistical analysis
Continuous variables (age, age at menarche, and age
at first full pregnancy) were analyzed using the
Mann–Whitney test. In the univariate analysis, associa-
tions between reproductive factors and breast cancer
were evaluated using the χ2-test. Multiple logistic
regression was used to calculate odds ratios (ORs) and
95% confidence intervals (CIs) as measures of the rela-
tive risk of cancers adjusted for age, age at menarche,
BMI, oral contraceptive use, benign breast disease, and
family history of breast cancer.
We fited different multivariate models: all cancer cases
(independent of molecular subtype) versus controls, and
luminal A and luminal B cases versus controls (selected at
random within 5-year age strata among 578 controls of the
study).
Statistical analyses were carried out using R (the R
Foundation for Statistical Computing; Version 3.0.3) and
P-values less than 0.05 were considered statistically
significant.
Results
Study population
The study population included a total of 864 pre-
menopausal White women: 286 breast cancer patients
diagnosed between 2006 and 2013 and 578 control
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participants selected between 2009 and 2014. The age of
the patients ranged from 21 to 49 years (median age:
44.5 years, interquartile range: 41–49), and that of the
control participants ranged from 23 to 49 years (median
age: 44 years, interquartile range: 41–49).
Pairing showed no differences with respect to each 5-year
age group (P= 0.90).
Reproductive factors and cancer risk in premenopausal
women
As shown in Table 1, reproductive factors did not sig-
nificantly relate to the risk of breast cancer in univariate
analysis. The mean age at menarche was 12.33± 1.49 years
in the case group and 12.51± 1.58 years in the control
group, with no differences on statistical analysis (P= 0.11);
the number of births was similar in the two groups: 69.2%
of parous women in the case group and 67.5% of parous
women in the control group (P= 0.60). The mean age at
first full-term pregnancy was 28.88± 5.51 years among the
patients and 28.78± 5.25 years among the control partici-
pants (P= 0.69). Therefore, the above-mentioned repro-
ductive factors were not associated with the risk of breast
cancer in premenopausal women.
Breastfeeding and cancer risk in premenopausal women
The distribution of risk factors among premenopausal
women with breast cancers compared with the controls is
shown in Table 1. In the multivariate analysis, parous
women who breastfed for up to 12 months were at a lower
risk of developing breast cancer (estimated OR: 0.41,
95% CI: 0.24–0.70, P= 0.0009). Women who had
breastfed for more than 12 months showed an increase in
the risk of breast cancer (OR: 2.32, 95% CI: 1.26–4.34,
P= 0.007). The other reproductive factors were not sig-
nificantly related to the risk of breast cancers (Table 2).
Reproductive factors and molecular subtypes of breast
cancer
To determine whether reproductive factors were asso-
ciated with different molecular subtypes of breast cancer,
280 out of 286 breast cancer archive tissue samples were
analyzed: 21 (8%) in-situ carcinoma, 117 (42%) luminal A
tumors, 94 (33%) luminal B tumors, 15 (5%) HER2+
tumors, and 33 (12%) triple-negative cancers. We exclu-
ded six cases: two because of missing data and four
because they did not fulfill the St. Gallen classification
criteria. For Ki-67 status, we chose the threshold greater
than or equal to 20%, which is used widely by patholo-
gists (Goldhirsch et al., 2013). We compared this classi-
fication of our cohort with that suggested by
Maisonneuve et al. (2014): only one of our cases of
luminal A was classifiable as luminal B and one of our
cases of luminal B was classifiable as luminal A. Thus, our
classification of the cohort did not differ significantly
from that suggested by Maisonneuve et al. (2014).
Moreover, in the analysis, patients with in-situ carcinoma
and nonluminal breast cancer were not included because
very few patients had these cancers.
We compared luminal A cases and luminal B cases
separately with a group of controls selected among 578
Table 1 Distribution of risk factors among women with breast
cancer (cases) and unaffected women (controls)a
Characteristics
Women with breast
cancer (286 cases)
Unaffected women
(578 controls) Ptrend
Age
Mean ±SD 43.3 ±4.8 43.5 ±4.23 0.90
Median (interquartile
range)
44.5 (41–49) 44.0 (41–49)
Range 21–49 23–49
Parity [n (%)] 0.60
Nulliparous 88 (30.8) 188 (32.5)
Parous 198 (69.2) 390 (67.5)
Age at menarche [n (%)]
Mean ±SD 12.3 ±1.5 12.5 ±1.6 0.11
<12 80 (28.5) 134 (23.4) 0.33
12 80 (28.5) 158 (27.6)
13 63 (22.4) 149 (26.0)
≥14 58 (20.6) 132 (23.0)
BMI (kg/m2) [n (%)] 0.34
<18.5 14 (5.0) 36 (6.3)
18.5–24.9 199 (71.3) 407 (70.7)
25–29.9 38 (13.6) 92 (16.0)
≥30 28 (10.0) 41 (7.0)
Oral contraceptive use
[n (%)]
0.60
Never 169 (61.2) 324 (58.0)
Current (at least for
5 years)
34 (12.3) 69 (12.3)
Former (at least for
5 years)
73 (26.5) 166 (29.7)
Parity [n (%)]
Number of births
(mean ±SD)
1.7 ±0.7 1.7 ±0.8 0.60
0 88 (30.8) 188 (32.5) 0.59
1 88 (30.8) 174 (30.1)
2 87 (30.4) 183 (31.7)
≥3 23 (8.0) 33 (5.7)
Benign breast disease
[n (%)]
0.02*
Yes 17 (5.9) 16 (2.8)
No 269 (94.1) 562 (97.2)
Family history of breast
cancer
0.14
None 160 (58.2) 350 (65.1)
First-degree familial
(<50 years)
24 (8.7) 39 (7.3)
Second-degree familial 91 (33.1) 148 (27.6)
Only parous women
Women with
breast cancer (198
cases)
Unaffected
women (390
controls) Ptrend
Age at first pregnancy [n (%)]
Mean ±SD 28.9 ±5.5 28.7 ± 5.3 0.51
<25 46 (23.2) 92 (23.8) 0.85
25–29 58 (29.3) 120 (31.1)
≥30 94 (47.5) 174 (45.1)
Breastfeeding [n (%)] 0.13
Yes 160 (80.8) 334 (85.6)
No 38 (19.2) 56 (14.4)
Breastfeeding duration [n (%)]
<0.001* ≤12 months 91 (45.0)
292
(74.9)
>12 months 69 (34.8) 42 (10.7)
No 38 (19.2) 56 (14.4)
aNumbers do not add up to the total because of missing values.
*Statistically significant.
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negative women of the study, respectively, always mat-
ched by age. Tables 3 and 4 show the distribution of risk
factors among luminal A and luminal B cases compared
with the controls. In the multivariate analysis, reproduc-
tive factors were not correlated significantly with luminal
A cancers (Table 5). In contrast, breastfeeding for up to
12 months did show a significant protective role for
luminal B breast cancers (OR: 0.22, 95% CI: 0.09–0.59,
P= 0.002), and, more interestingly, it was the only
reproductive factor that was statistically significant in the
multivariate analysis (Table 6). However, breastfeeding
for more than 12 months was not a protective factor in
both luminal A and luminal B molecular subtypes (NS).
Discussion
Our study analyzed the role of breastfeeding and repro-
ductive factors in the risk of breast cancer in a homo-
genous selected population of White premenopausal
women living in a country with a high risk of breast
cancer, focusing on luminal molecular phenotypes, the
most frequent cancers occurring in the population sample
(75%).
Parity was shown to be a protective factor for breast cancer
in postmenopausal women, but not in premenopausal
women (Clavel-Chapelon, 2002). Accordingly, our results
confirm that in premenopausal women, the parity did not
reduce the risk of breast cancer. In contrast to the results
reported by other authors, we cannot conclude that the lack
of a protective effect of multiparity is because of the low
Table 2 Multivariable-adjusted odds ratios for breast cancer (only
parous women)
Women with breast cancer (198
cases)
Unaffected women (390 controls)
Characteristics ORa 95% CI P-value
Age at menarche
<12 1.01 0.60–1.69 0.97
12 1 Reference –
13 0.87 0.51–1.51 –
≥14 0.81 0.45–1.43 –
BMI (kg/m2)
<18.5 0.5 0.17–1.29 0.18
18.5–24.9 1 Reference –
25–29.9 0.68 0.37–1.19 0.18
≥30 1.25 0.58–2.62 0.56
Oral contraceptive use
Never 1.16 0.75–1.83 0.51
Current (at least for 5 years) 1 Reference –
Former (at least for 5 years) 1.15 0.59–2.22 0.68
Benign breast disease
No 1 Reference –
Yes 1.96 0.77–4.88 0.22
Family history of breast cancer
None 1 Reference –
First-degree familial
(<50 years)
1.37 0.64–2.83 0.40
Second-degree familial 1.31 0.84–2.02 0.23
Breastfeeding duration
No 1 Reference –
≤12 months 0.41 0.24–0.70 <0.001*
>12 months 2.32 1.26–4.34 0.007*
CI, confidence interval; OR, odds ratio.
aOdds ratios are adjusted for age, age at menarche, BMI, oral contraceptive use,
benign breast disease, and family history of breast cancer.
*Statistically significant.
Table 3 Distribution of risk factors among women with luminal A
breast cancer and unaffected womena
Characteristics
Women with luminal A
breast cancer
(N=117)
Unaffected women
(controls) (N=234) Ptrend
Age
Mean ±SD 44.4 ± 4.4 44.0 ± 4.2
Median (interquartile
range)
45 (43–48) 45 (42–47) 0.37
Range 25–49 23–49
Parity [n (%)] 0.29
Nulliparous 32 (27.4) 77 (32.9)
Parous 85 (72.6) 157 (67.1)
Age at menarche [n (%)]
Mean ±SD 12.4 ±1.5 12.3 ±1.5 0.73
<12 35 (30.2) 63 (27.0) 0.20
12 27 (23.4) 64 (27.5)
13 27 (23.4) 59 (25.3)
≥14 27 (23.4) 47 (20.2)
BMI (kg/m2) [n (%)] 0.75
<18.5 7 (6.1) 13 (5.6)
18.5–24.9 82 (71.3) 160 (68.4)
25–29.9 15 (13.0) 41 (17.5)
≥30 11 (9.6) 20 (8.5)
Oral contraceptive use
[n (%)]
0.19
Never 64 (57.1) 137 (60.9)
Current (at least for
5 years)
18 (16.1) 21 (9.3)
Former (at least for
5 years)
30 (26.8) 67 (29.8)
Parity [n (%)]
Number of births
(mean ±SD)
1.7 ±0.7 1.6 ±0.6 0.65
0 32 (27.4) 77 (32.9) 0.52
1 39 (33.3) 35 (32.5)
2 36 (30.8) 31 (29.5)
≥3 10 (8.5) 9 (5.2)
Benign breast disease
[n (%)]
0.19
Yes 7 (6.0) 7 (3.0)
No 110 (94.0) 227 (97.0)
Family history of breast
cancer [n (%)]
0.22
First-degree familial
(<50 years)
7 (6.3) 19 (9.5)
Second-degree
familial
43 (38.4) 59 (29.5)
None 62 (55.4) 122 (61.0)
Only parous women
Women with
luminal A
breast
cancer
(N=85)
Unaffected women
(controls) (N=157) Ptrend
Age at first pregnancy [n (%)]
Mean ±SD 29.7 ±5.7 28.7 ± 5.2 0.59
<25 16 (18.8) 36 (23.4) 0.30
25–29 22 (25.9) 49 (31.8)
≥30 47 (55.3) 69 (44.8)
Breastfeeding [n (%)] 0.90
Yes 72 (84.7) 132 (84.0)
No 13 (15.3) 25 (16.0)
Breastfeeding duration [n (%)]
<0.001*
≤12 months 46 (54.1) 115 (73.2)
>12 months 26 (30.6) 17 (10.8)
No 13 (15.3) 25 (16.0)
aNumbers do not add up to the total because of missing values.
*Statistically significant.
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number of multiparous young women: the births were not
correlated to the risk of breast cancer in a statistically sig-
nificant sample of multiparous women. Moreover, we
found that younger age at first full-term pregnancy did not
confer protection; no significant increase in the risk of
cancer was found both for multiparity and for age at
menarche. Interestingly, familial history of breast cancer of
both first and second grade in our cohort of premenopausal
women was not significantly related to the risk of breast
cancer. This can be attributed to the lack of a significant
number of cases with first-grade familial history of breast or
ovarian cancer at a young age, which is highly related to an
increased risk of breast cancer (six cases).
Literature data show that reproductive factors are related
to the molecular subtypes of breast cancer (Althuis et al.,
2004; Ursin et al., 2005; Tamimi et al., 2012); hormonal
factors have a greater impact on luminal than nonluminal
types of breast cancer, the risk being predominantly
influenced by hormonal mechanisms (Anderson, 2002;
Dickson and Stancel, 2000; Anderson et al., 2014).
Hormonal risk factors such as parity and early age at first
birth seem to relate positively to luminal subtypes com-
pared with nonluminal tumors (Ma et al., 2006). Previous
studies have suggested a protective effect of multiparity
and young age at first full-term pregnancy on breast
cancer, but this protective effect appears to be different
among the various breast cancer receptor statuses: mul-
tiparity seems to exert a protective effect on ER+ /PR+
tumors, but not on receptor-negative ones (Yoo et al.,
1997; Cotterchio et al., 2003; Ursin et al., 2005; Kwan et al.,
2009). Recently, a large population-based prospective
Table 4 Distribution of risk factors among women with luminal B
breast cancer and unaffected womena
Characteristics
Women with luminal
B breast cancer
(N=94)
Unaffected women
(controls) (N=188) Ptrend
Age
Mean ±SD 42.8 ±4.9 42.8 ±5.4
Median (interquartile
range)
44 (40–46) 44 (41–47) 0.72
Range 21–49 21–49
Parity [n (%)] 0.21
Nulliparous 27 (28.7) 68 (36.2)
Parous 67 (71.3) 120 (63.8)
Age at menarche [n (%)]
Mean ±SD 12.4 ±1.5 12.5 ±1.5 0.28
<12 24 (26.1) 41 (21.8) 0.51
12 29 (31.5) 57 (30.3)
13 18 (19.6) 52 (27.7)
≥14 21 (22.8) 38 (20.2)
BMI (kg/m2) 0.58
<18.5 4 (4.3) 15 (7.9)
18.5–24.9 66 (71.7) 134 (71.3)
25–29.9 14 (15.2) 28 (14.9)
≥30 8 (8.8) 11 (5.9)
Oral contraceptive use 0.06
Never 60 (65.9) 93 (51.1)
Current (at least for
5 years)
9 (9.9) 31 (17.0)
Former (at least for
5 years)
22 (24.2) 58 (31.9)
Parity
Number of births
(mean ±SD)
1.7 ±0.7 1.7 ± 0.6 0.80
0 27 (28.7) 68 (36.2) 0.25
1 31 (33.0) 44 (23.4)
2 28 (29.8) 64 (34.0)
≥3 8 (8.5) 12 (6.4)
Benign breast disease
[n (%)]
0.38
Yes 3 (3.2) 3 (1.6)
No 91 (96.8) 185 (98.4)
Family history of breast
cancer [n (%)]
0.26
First-degree familial
(<50 years)
7 (7.7) 15 (8.0)
Second-degree
familial
27 (29.7) 42 (22.3)
None 57 (62.6) 131 (69.7)
Only parous women
Women with luminal
B breast cancer
(N=67)
Unaffected women
(controls) (N=120) Ptrend
Age at first pregnancy [n (%)]
Mean ±SD 28.2 ±5.3 28.4 ±4.9 0.65
<25 16 (22.9) 33 (27.5) 0.75
25–29 24 (35.8) 37 (30.8)
≥30 27 (40.3) 50 (41.7)
Breastfeeding [n (%)] 0.01*
Yes 51 (76.1) 108 (90.0)
No 16 (23.9) 12 (10.0)
Breastfeeding
duration [n (%)]
<0.001*
≤12 months 25 (37.3) 97 (80.8)
>12 months 26 (38.8) 11 (9.2)
No 16 (22.9) 12 (10.0)
aNumbers do not add up to the total because of missing values.
*Statistically significant.
Table 5 Multivariable-adjusted odds ratios for breast cancer (only
parous women)
Women with luminal A breast cancer
(N=85)
Unaffected women (controls)
(N=157)
Characteristics ORa 95% CI P-value
Age at menarche
<12 1.27 0.57–2.85 0.56
12 1 Reference –
13 0.95 0.39–2.3 0.90
≥14 1.1 0.48–2.73 0.84
BMI (kg/m2)
<18.5 0.73 0.14–3.0 0.67
18.5–24.9 1 Reference –
25–29.9 0.46 0.16–1.15 0.11
≥30 1.05 0.32–3.15 0.93
Oral contraceptive use
Never 1.13 0.57–2.25 0.73
Current (at least for 5 years) 1 Reference –
Former (at least for 5 years) 2.09 0.74–6.0 0.16
Benign breast disease
No 1 Reference –
Yes 3.64 0.92–5.0 0.06
Family history of breast cancer
None 1 Reference –
First-degree familial
(<50 years)
0.82 0.23–2.60 0.74
Second-degree familial 1.2 0.61–2.35 0.58
Breastfeeding duration
No 1 Reference –
≤12 months 0.55 0.18–1.65 0.28
>12 months 2.43 0.87–7.01 0.09
CI, confidence interval; OR, odds ratio.
aOdds ratios are adjusted for age, age at menarche, BMI, oral contraceptive use,
benign breast disease, and family history of breast cancer.
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study with long-term follow-up (Horn et al., 2014) con-
firmed that the associations of reproductive factors with
the risk of breast cancer may vary according to different
molecular subtypes. They found that early menarche,
older age at first birth, and low parity were associated
with an increased risk for luminal breast cancer, whereas
for the nonluminal type, there were no associations.
We found that age at menarche, parity, and age at first
full-term pregnancy did not affect luminal A and luminal
B breast cancers in our cohort of premenopausal women.
Reports of large series observed a protective effect in the
cohorts of both premenopausal and postmenopausal
women (Ursin et al., 2005; Kobayashi et al., 2012;
Anderson et al., 2014). In the population of pre-
menopausal women, breastfeeding was found to be pro-
tective in some studies (Collaborative Group on
Hormonal Factors in Breast Cancer, 2002; Shema et al.,
2007; Nelson et al., 2012; Warner et al., 2013;
Trentham-Dietz et al., 2014), but not in others (Tessaro
et al., 2003; Shantakumar et al., 2007; Butt et al., 2014).
Several studies (Phipps et al., 2008; Butt et al., 2014; Horn
et al., 2014) and meta-analyses (Collaborative Group on
Hormonal Factors in Breast Cancer, 2002; Althuis et al.,
2004) were published to better clarify the effect of
breastfeeding and reproductive factors on the incidence
of different breast cancer subtypes, and the majority of
published data were from postmenopausal women
(Phipps et al., 2008; Horn et al., 2014) or a large study
population of both premenopausal and postmenopausal
breast cancer patients (Kelsey et al., 1993; Ursin et al.,
2005).
On multivariate analysis, we found that breastfeeding up
to 12 months reduced the risk of luminal B but not
luminal A breast cancer in this selected population.
Breastfeeding was found to protect against both ER+ /
PR+ and ER− /PR− tumors (Huang et al., 2000a; Ursin
et al., 2005; Ma et al., 2006; Kwan et al., 2009). Other
studies showed a reduced risk of basal-like triple nega-
tive breast cancer among women who breastfed for more
than 4 months in African-American and White women, or
in African-American women only (Millikan et al., 2008;
Palmer et al., 2014). It is noteworthy that, in our study,
among luminal cancers, only luminal B cancer was sig-
nificantly related to breastfeeding. It might be con-
ceivable, as suggested by several studies (Ma et al., 2006;
Phipps et al., 2008; Kobayashi et al., 2012), that breast-
feeding acts through different hormonal mechanisms
than parity, thus determining the risk for different sub-
types of breast cancer. In this respect, it cannot be
excluded that the same factors might also play a role in
determining the tumor aggressiveness in those estab-
lished cancers. However, we cannot support any con-
clusion on the incidence of HER2+ or triple-negative
cancers and breastfeeding because of the low number
of cases.
Unexpectedly, overall, breastfeeding for more than
12 months was not linked to breast cancer risk reduction
in our population of premenopausal women compared
with those who never breastfed, for both luminal A and B
cancers (Tables 5 and 6). These findings seem to be
in contrast to the results of a large meta-analysis
(Collaborative Group on Hormonal Factors in Breast
Cancer, 2002) and other reports (Shema et al., 2007;
Nelson et al., 2012; Trentham-Dietz et al., 2014) that
indicate that the longer women breastfeed, the more they
are protected against breast cancer. However, we would
like to report observations of two other studies (Huang
et al., 2000b; Yang and Jacobsen, 2008) that did not show
an association between increased duration of lactation
and reduction of the risk of breast cancer. Moreover,
Gustbee et al. (2013) reported a high risk for early events
of breast cancer for a total duration of breastfeeding of
more than 12 months, perhaps because of the pro-
proliferation effect of prolactin. Furthermore, three
case–control studies showed that longer breastfeeding
duration was a risk factor for breast cancers: a multicenter
case–control study carried out in Italy (Negri et al., 1996),
a Turkish study (Ulusoy et al., 2010), and a recent Serbian
study (Ilic et al., 2015). A large Italian study (Negri et al.,
1996) included premenopausal and postmenopausal
women and excluded any appreciable protective role for
Table 6 Multivariable-adjusted odds ratios for breast cancer (only
parous women)
Women with luminal B breast cancer
(N=67)
Unaffected women (controls)
(N=120)
Characteristics ORa 95% CI P-value
Age at menarche
<12 0.99 0.38–2.60 0.99
12 1 Reference –
13 0.81 0.28–2.29 0.70
≥14 1.17 0.42–3.24 0.76
BMI (kg/m2)
<18.5 0.33 0.04–1.84 0.25
18.5–24.9 1 Reference –
25–29.9 0.91 0.32–2.39 0.84
≥30 1.20 0.32–4.49 0.78
Oral contraceptive use
Never 1.42 0.61–3.28 0.42
Current (at least for 5 years) 1 Reference –
Former (at least for 5 years) 0.62 0.17–2.05 0.44
Benign breast disease
No 1 Reference –
Yes 1.52 0.15–11.60 0.69
Family history of breast cancer
None 1 Reference –
First-degree familial
(<50 years)
1.28 0.33–4.59 0.70
Second-degree familial 1.29 0.55–2.96 0.54
Breastfeeding duration
No 1 Reference –
≤12 months 0.22 0.09–0.59 0.002*
>12 months 2.15 0.70–6.78 0.18
CI, confidence interval; OR, odds ratio.
aOdds ratios are adjusted for age, age at menarche, BMI, oral contraceptive use,
benign breast disease, and family history of breast cancer.
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lactation independent of the duration of breastfeeding.
Ulusoy et al. (2010) investigated a population of both
premenopausal and postmenopausal Turkish women,
showing that a 10-month increase in breastfeeding
increased the risk of breast cancer by 8% (OR: 1.008, 95%
CI: 1.003–1.012, P= 0.0001). Nevertheless, this study
does not indicate whether the OR has been adjusted for
the other factors analyzed in a multivariate manner.
Finally, Ilic et al. (2015) reported that in women living in
Serbia, the risk of breast cancer increases with the dura-
tion of breastfeeding (OR: 3.44, 95% CI: 1.15–10.24,
P= 0.023; for women who breastfed >13 months). Also,
in this case, a sample of both premenopausal and post-
menopausal women was analyzed. Our analysis indicates
that breastfeeding for more than 12 months increases the
risk of breast cancer, considering all breast cancer cases,
but we cannot conclude on a general negative relation
because of the fact that significance was not achieved on
stratifying luminal A and luminal B cases.
In contrast to the results reported by these authors (Negri
et al., 1996; Ulusoy et al., 2010; Ilic et al., 2015), we found
lactation up to 12 months to be a protective factor for
luminal B cancer and our study showed some differences:
(a) our cohort was homogeneous and included pre-
menopausal White women; (b) our results were obtained
by matching one case with two controls (1 : 2 case–control
study); and (c) our study considered the molecular phe-
notype of breast cancers. It is noteworthy that we did not
observe a reduction in the risk of breast cancer in relation
to breastfeeding, but a less aggressive cancer in breast-
feeding women that depends on the duration of lactation.
In women with more than 12 months of lactation, the lack
of breastfeeding protection was not expected. As in the
majority of the literature, we considered the total dura-
tion of breastfeeding derived from the sum of the
breastfeeding months for all children (if more than one)
for each woman. To clarify this point, we analyzed
whether there is a difference related to more than
12 months of lactation in women with one child (88 cases/
174 controls). The results confirmed that breastfeeding
for more than 12 months was not protective in multi-
variate analysis. The same results were found for the case
group of women with two children. In this respect, we
underline that, in our cohort of cases, the majority of
women had one or two children (175 cases/357 controls).
Thus, the results obtained on the total duration of
breastfeeding appear to be consistent. We cannot
exclude that breastfeeding for more than 12 months
might be a protective factor or might contribute toward
increasing the risk of breast cancer depending on the
type of population analyzed (i.e. race). Although overall
observations showed that breastfeeding for more than
12 months was not protective, further investigations on a
higher number of cases are necessary.
In conclusion, this study of a homogeneous cohort of
White premenopausal women showed no statistical
associations between age at menarche, parity, age at first
birth, and number of births and the risk of breast cancer.
In contrast, the study supports evidence that, among
luminal breast cancers, breastfeeding for up to 12 months
is strongly protective against the more aggressive luminal
B rather than the less aggressive luminal A type.
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